Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).

Non-arteritic Ischemic Optic Neuropathy Clinical Trial

Official title:
A Preliminary Double Blind Clinical Study, Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).

Status Completed

Clinical Trial Summary

The study objectives are to assess any changes in visual acuity and visual field observed following the administration of RPh201 during an overall treatment period of at least 13 consecutive weeks with an option to extended the treatment phase to another 13 weeks (26 weeks total), and at the follow-up visit at 3 month after end of treatment in patients with optic nerve neuropathy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Ischemia
Non-arteritic Ischemic Optic Neuropathy
Optic Nerve Diseases
Optic Nerve Injuries
Optic Neuropathy, Ischemic
Peripheral Nervous System Diseases

Clinical Trial Details

NCT number	NCT02045212
Study type	Interventional
Source	Regenera Pharma Ltd
Contact
Status	Completed
Phase	Phase 2
Start date	February 2014
Completion date	December 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT06031350` - Peripapillary and Macular Vascular Changes of Unilateral Anterior Ischemic Optic Neuropathy: An Optical Coherence Tomography Angiography Study
Completed	`NCT03758118` - Citicoline in Non-Arteritic Ischemic Optic Neuropathy	N/A
Recruiting	`NCT05305079` - NA-AION Risk Factors: New Perspectives
Completed	`NCT01614158` - Assessment of Visual Field-related Endpoints in Patients With Non-arteritic Ischemic Optic Neuropathy	N/A